Golden State Medical Supply Recalls Irbesartan Tablets Due to Impurity
Golden State Medical Supply is recalling 12,502 bottles of Irbesartan 300 mg tablets because FDA testing found the impurity N-nitrosodiethylamine (NDEA).
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves the presence of a nitrosamine impurity (NDEA), which is a significant health hazard warranting a Severe rating under the rubric for significant injury/property-damage reports or high-risk contamination.
Plain-English summary
Golden State Medical Supply Inc. is recalling 12,502 bottles of IRBESARTAN Tablets, USP 300 mg. The affected products are available in 30-count and 90-count bottles and were distributed throughout the United States. The recall is due to Current Good Manufacturing Practice (CGMP) deviations.
FDA laboratory testing confirmed the presence of an impurity, N-nitrosodiethylamine (NDEA), in the product. The agency has classified this recall as Class II.
Consumers should stop using the recalled medication and contact their healthcare provider for further instructions. The specific lot numbers and expiration dates for the affected 30-count and 90-count bottles are listed in the official recall documentation.
The recalled product
- Product
- IRBESARTAN Tablets, USP 300 mg (a) 30-count bottle (NDC 60429-642-30), (b) 90-count bottle (NDC 60429-642-90) Rx Only, Manufactured by: SciGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Distributed by: GSMS, Incorporated, Camarillo, CA 93012, USA.
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 12,502
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (14)
- Lot Numbers: 30-count bottles GS019036
- Exp 09/19 GS019073
- Exp. 09/19 GS021472
- Exp. 11/19 GS021530
- Exp. 11/19 GS022234
- Exp. 02/20 90-count bottles B162009
- Exp. 09/19 B162010
- Exp. 09/19 B162011
- Exp. 09/19 B162012
- Exp. 11/19 B162013
- Exp. 11/19 B162014
- Exp. 11/19 B162015
- Exp. 11/19 C162001
- Exp. 02/20
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 3 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17